

# Achieving Viral Suppression in 90% of People Living With Human Immunodeficiency Virus on Antiretroviral Therapy in Low- and Middle-Income Countries: Progress, Challenges, and Opportunities

Jean B. Nachega,<sup>1,2,3</sup> Nadia A. Sam-Agudu,<sup>4,5,6</sup> Lynne M. Mofenson,<sup>7</sup> Mauro Schechter,<sup>8,a</sup> and John W. Mellors<sup>9,a</sup>

<sup>1</sup>Departments of Epidemiology, Infectious Diseases and Microbiology, University of Pittsburgh Graduate School of Public Health, Pennsylvania, and <sup>2</sup>Departments of Epidemiology and International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland; <sup>3</sup>Department of Medicine and Centre for Infectious Diseases, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa; <sup>4</sup>Institute of Human Virology, University of Maryland School of Medicine, Baltimore; <sup>5</sup>International Research Center of Excellence, Institute of Human Virology Nigeria, Abuja; <sup>6</sup>Department of Paediatrics, University of Cape Coast School of Medical Sciences, Ghana; <sup>7</sup>Elizabeth Glaser Pediatric AIDS Foundation, Washington, D.C.; <sup>8</sup>Projeto Praga Onze, Universidade Federal do Rio de Janeiro, Brazil; and <sup>9</sup>Division of Infectious Diseases, University of Pittsburgh, School of Medicine, Pennsylvania

Although significant progress has been made, the latest data from low- and middle-income countries show substantial gaps in reaching the third “90%” (viral suppression) of the UNAIDS 90-90-90 goals, especially among vulnerable and key populations. This article discusses critical gaps and promising, evidence-based solutions. There is no simple and/or single approach to achieve the last 90%. This will require multifaceted, scalable strategies that engage people living with human immunodeficiency virus, motivate long-term treatment adherence, and are community-entrenched and -supported, cost-effective, and tailored to a wide range of global communities.

**Keywords.** human immunodeficiency virus (HIV); 90-90-90; antiretroviral therapy (ARV); viral suppression; low- and middle-income countries (LMICs).

There are currently nearly 11 million persons living with human immunodeficiency virus (HIV) who need to achieve the third “90” (viral suppression) UNAIDS target by 2020, not including the 3–5 million new infections expected between 2017 and 2020 [1, 2]. Of note, regional differences in viral suppression rates exist between low- and middle-income countries (LMICs) compared with high-income countries; for example, in sub-Saharan Africa, eastern and southern countries had better suppression

rates (50%) than countries in the west/central region (25%) [3]. Herein and in Table 1, we discuss barriers and potential solutions to achieve the third “90” of the HIV care cascade in high-burden LMICs.

## DIFFERENTIATED SERVICE DELIVERY MODELS TO ACHIEVE VIRAL SUPPRESSION

Differentiated service delivery (DSD) models simplify and decentralize HIV care by adapting services across the care cascade to the preferences and expectations of different subpopulations of persons living with HIV. Examples of DSD initiatives include shifting tasks to lower-cadre healthcare workers to mitigate human resource shortages and community-based antiretroviral therapy (ART) clubs (CACs), which provide adherence support and fast-track ART refills. In South Africa, CAC (vs community-based clinics) participation was associated with a 67% reduction in the risk of loss to follow-up (adjusted hazard ratio, 0.33; 95% confidence

interval [CI], .27–.40) and breakthrough viremia (adjusted hazards ratio, 0.53; 95% CI, .51–.55) [4]. Also, DSD models have been shown to be cost-effective [5]. However, task shifting may face implementation barriers in selected LMICs (eg, Brazil, Argentina, Mexico, and Puerto Rico), where a physician needs to be present to sign-off on all prescriptions [6]. Such barriers lower care efficiency and should be reevaluated to improve patient outcomes.

## SAME-DAY ANTIRETROVIRAL THERAPY INITIATION TO IMPROVE VIROLOGIC OUTCOMES

A systematic review and meta-analysis based on trial data from South Africa, Haiti, and Uganda showed that ART initiation on the same day as HIV diagnosis increased viral suppression (relative risk, 1.17; 95% CI, 1.07–1.27) and improved 12-month retention (relative risk, 1.11; 95% CI, .99–1.26) [7]. However, 1 year after ART initiation,

Received 17 November 2017; editorial decision 27 December 2017; accepted 6 January 2018; published online January 8, 2018.

<sup>a</sup>M. S. and J. W. M. contributed equally.

Correspondence: J. B. Nachega, Department of Epidemiology, University of Pittsburgh Graduate School of Public Health, 130 DeSoto St, 503 Parran Hall, Pittsburgh, PA (jbn16@pitt.edu).

Clinical Infectious Diseases® 2018;66(10):1487–91

© The Author(s) 2018. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com. DOI: 10.1093/cid/ciy008

**Table 1. Achieving 90% Viral Suppression in Low- and Middle-Income Countries: Target Populations, Challenges, and Opportunities**

Target HIV-Infected Population	Challenges	Priority Solutions
General	<ul style="list-style-type: none"> <li>Late HIV diagnosis and delayed initiation of ART</li> </ul>	<ul style="list-style-type: none"> <li>Expanded and consistent access to HIV testing, including independent testing for adolescents<sup>a</sup></li> <li>Peer psychosocial support for HIV testing and initiation of ART</li> <li>Same-day ART initiation<sup>a</sup></li> </ul>
Pregnant and breastfeeding women	<ul style="list-style-type: none"> <li>Poor ART adherence and retention in care, especially postpartum</li> <li>Postpartum VL testing after stopping ART</li> <li>Fear of HIV status disclosure</li> <li>Postpartum depression</li> <li>Lack of social and male partner support</li> <li>Gender inequity</li> </ul>	<ul style="list-style-type: none"> <li>Prioritization of VL testing in pregnant and breastfeeding women<sup>a</sup></li> <li>Integrate HIV/PMTCT gender-based violence programming<sup>a</sup></li> <li>Peer support for mental health, disclosure, ART adherence, and retention in care</li> <li>Improve male partner participation in HIV care for women</li> </ul>
Children	<ul style="list-style-type: none"> <li>Missed opportunities for early infant diagnosis</li> <li>Limited pediatric antiretroviral drug formulations</li> <li>Limited caregiver competency</li> <li>Poor virologic suppression</li> </ul>	<ul style="list-style-type: none"> <li>Point-of-care virologic infant HIV diagnostic testing<sup>a</sup></li> <li>Improved access to newer antiretroviral drugs in pediatric formulations<sup>a</sup></li> <li>Family-centered, community-based care</li> </ul>
Adolescents	<ul style="list-style-type: none"> <li>Missed opportunities for diagnosis</li> <li>Linkage, adherence, viral suppression, and retention in care</li> <li>Lack of disclosure to perinatally infected youth</li> <li>Poor healthcare transitioning procedures</li> </ul>	<ul style="list-style-type: none"> <li>Legally protected, independently accessible HIV testing<sup>a</sup></li> <li>Individual and/or group peer support</li> <li>Comprehensive healthcare transition guidelines</li> <li>Adolescent-friendly services, including peer support</li> <li>Anticipatory HIV disclosure guidance for healthcare workers, parents/guardians, and youth</li> <li>Robust healthcare transition as part of differentiated care<sup>a</sup></li> </ul>
LGBT community	<ul style="list-style-type: none"> <li>Stigma</li> <li>Criminalization and targets of violence in some countries</li> </ul>	<ul style="list-style-type: none"> <li>Advocacy for human rights<sup>a</sup></li> <li>Decentralized, community-based, differentiated service delivery models, including testing, access to ART, adherence counseling, VL monitoring</li> <li>Safe spaces for HIV care and treatment</li> </ul>
Sex workers	<ul style="list-style-type: none"> <li>Stigma</li> <li>Gender violence</li> <li>Criminalization in some countries</li> </ul>	<ul style="list-style-type: none"> <li>Advocacy for human rights<sup>a</sup></li> <li>Adapted, integrated services, including gender-based violence prevention and outreach for testing and ART</li> <li>Safe spaces for HIV care and treatment</li> <li>Differentiated service delivery including testing, access to ART, adherence counseling, VL monitoring</li> </ul>
People who inject drugs	<ul style="list-style-type: none"> <li>Stigma</li> <li>Criminalization in some countries</li> </ul>	<ul style="list-style-type: none"> <li>Advocacy for human rights<sup>a</sup></li> <li>Integration and linkage of HIV and drug abuse treatment<sup>a</sup></li> <li>Adapted services, including outreach for testing and ART</li> <li>Differentiated service delivery, including testing, access to ART, adherence counseling, VL monitoring, DAART</li> <li>Safe spaces for HIV care and treatment</li> </ul>
Prisoners	<ul style="list-style-type: none"> <li>Stigma</li> <li>Poorly resourced health services</li> </ul>	<ul style="list-style-type: none"> <li>HIV testing with linkage to care and DAART during incarceration<sup>a</sup></li> <li>Linkage to care with support upon release<sup>a</sup></li> </ul>

Abbreviations: ART, antiretroviral therapy; DAART, directly administered ART; HIV, human immunodeficiency virus; LGBT, lesbian, gay, bisexual, and transgender; PMTCT, prevention of mother-to-child HIV transmission; VL, viral load.

<sup>a</sup>Especially important.

retention in care and viral suppression were well below 90%. Nonetheless, these findings informed a recent World Health Organization (WHO) recommendation to scale up same-day ART initiation, especially for those at high mortality risk (CD4 count <200 cells/mm<sup>3</sup> or WHO clinical stage 3 or 4 disease); pregnant women (to reduce mother-to-child HIV transmission [MTCT]); and patients with acute HIV infection due to high sexual transmission risk. Due to potential life-threatening immune reconstitution inflammatory syndrome following rapid ART initiation, patients

with tuberculosis and cryptococcal meningitis are excluded [8, 9].

## REACHING VULNERABLE POPULATIONS

### Pregnant and Postpartum Women

Viral suppression is critical for pregnant/breastfeeding women because sustained viremia reduces the impact of ART for prevention of MTCT (PMTCT) and maternal health, but there has been limited implementation of viral load (VL) monitoring [10]. Viral load measurement at 36 weeks gestation may be most predictive of viremia at delivery,

identifying HIV-exposed infants who should receive enhanced antiretroviral prophylaxis [11, 12].

Disengagement from PMTCT services is unacceptably high, especially postpartum, with a sizable proportion of women (~30%) experiencing at least 1 episode of viral rebound in this period [13, 14]. Postpartum transfer from PMTCT services to general HIV care is an important but neglected step in the HIV care cascade for pregnant women; studies are evaluating whether continued ART provision via PMTCT programs during breastfeeding would improve maternal

retention and viral suppression [15]. Differentiated service delivery involving referral to lay counsellor-operated CACs resulted in improved retention outcomes among postpartum women [16]. Other studies show higher viral suppression rates among women who have disclosed their HIV status to male partners [17]. A structured PMTCT peer-support intervention in Nigeria was successful in improving retention (adjusted odds ratio = 5.9; 95% CI, 3.0–11.6) and viral suppression (adjusted odds ratio, 4.9; 95% CI, 2.6–9.2) among postpartum women [18]. Similarly, a South African study reported that mHealth and/or peer support for ART adherence were acceptable and feasible among pregnant women initiating life-long ART [19]. Finally, strategies to improve male partner involvement and to mitigate gender-based violence are important [20].

#### Children and Adolescents

Although there have been pediatric HIV treatment gains, only 50% of HIV-infected children received ART in 2015. Viral suppression among children and adolescents in LMICs remains far below that in high-income countries [21, 22]. Antiretroviral therapy adherence and viral suppression have been particularly challenging among adolescents and youth living with HIV [23].

A DSD designed to reduce patient-level barriers and maximize health system efficiency in rural Uganda and Kenya showed promise in improving retention and viral suppression among adults and children [24]. Community-based support for caregivers was associated with improved retention and viral suppression among children and adolescents in Zimbabwe [25], and an integrated, family-based model of care resulted in increased enrollment of children in care and initiating ART in Uganda [15, 26]. Transition from pediatric to adult HIV care is a particularly vulnerable time for loss-to-follow-up among youth; a variety of models to facilitate transition in LMICs

have been developed, but outcomes data are limited [27].

#### KEY POPULATIONS: MEN WHO HAVE SEX WITH MEN, PEOPLE WHO INJECT DRUGS, FEMALE SEX WORKERS, AND TRANSGENDER INDIVIDUALS

In a prospective study among 793 HIV-tested men who have sex with men (MSM) and transgender individuals in Brazil, 131 (16.5%) were HIV-infected; 95 (72.5%) were linked to HIV care, 80 (61.1%) initiated ART, and only 50 (38.2%) were suppressed 1 year after diagnosis [28]. Among 1146 HIV-infected MSM in India, only 30% were aware of their HIV-positive status, 23% were linked to care, 16% had started ART, and 10% were virally suppressed [29]. Data collected among female sex workers in Johannesburg, South Africa, documented poor viral suppression, with 81% not receiving ART [30]. Also, injection drug use has been documented in 20 African countries [31]. In Kenya, predicted HIV prevalence 5 years after initiating injection drug use was nearly 20% in Nairobi and 17% in the coastal region; <5% in both regions were virally suppressed [32]. Decentralized care with unfettered access to DSD (eg, specific clinics for MSM, female sex workers, or people who inject drugs) could help infected persons achieve and sustain viral suppression. Furthermore, efforts targeting stigma, discrimination, and human rights violations, including protective and empowering legal environments, are urgently needed.

#### COMMUNITY-BASED COMBINATION HUMAN IMMUNODEFICIENCY VIRUS INTERVENTIONS

A Botswana combination prevention project documented that among 2609 individuals receiving ART with a VL measurement, 2517 (96.5%; 95% CI, 96.0–97.0) had a suppressed VL [33]. Community-based testing and ART initiation in rural Kenya and Uganda achieved 90% virologic

suppression within 2 years of program implementation [34]. Recent population-based HIV impact assessments from Zimbabwe, Malawi, and Zambia reported viral suppression in 89% of persons living with HIV on ART in these countries; however, there were substantially lower viral suppression rates among men, adolescents and young adults, and children [35]. In the HPTN071/PopART TasP trial in Zambia, after two rounds of delivering the intervention, 90% of HIV+ women and about 80% of HIV+ men were estimated to know their HIV+ status. Of those known HIV+, an estimated 80% were on ART; but VL data is not yet available [36]. In the ANRS 12249 TasP trial in KwaZulu-Natal, South Africa, 68.8% of an estimated 3933 persons living with HIV were newly diagnosed, of whom 70.1% and 70.8% were initiated on ART and virally suppressed, respectively [37].

#### ROBUST FIRST-LINE ANTIRETROVIRAL THERAPY, PROACTIVE ADHERENCE MONITORING, AND POINT-OF-CARE VIRAL LOAD AND HUMAN IMMUNODEFICIENCY VIRUS DRUG-RESISTANCE TESTING

There is no gold standard to monitor ART adherence, but real-time adherence monitoring tools such as electronic drug monitoring and electronic pharmacy refill tracking systems can be useful to prompt evidence-based adherence interventions (eg, peer counseling and/or mHealth) among patients with documented poor adherence before breakthrough viremia and emergence of drug resistance [38]. Due to the relative low cost, electronic pharmacy refill tracking systems are likely to be cost-effective and scalable in LMICs. Increased VL monitoring access can serve as a metric for optimal ART adherence; in most LMICs, persons living with HIV with unsuppressed VLs resuppress following enhanced adherence counseling, indicating viremia was largely due to nonadherence [39].

A recent systematic review and meta-analysis found the annual increase in the odds of detecting pretreatment HIV drug resistance between 1996 and 2016 were 23% in southern Africa, 17% in western and central Africa, and 11% in Asia [40]. Access to affordable, point-of-care HIV VL assays and genotypic drug-resistance testing could facilitate better ART regimen choices. Assessments for 2 major nucleoside reverse transcriptase inhibitor-associated mutations (M184V and K65R) and 4 major non-nucleoside reverse transcriptase inhibitor-associated mutations (K103N, Y181C, G190A, and V106M) would be the most useful for point-of-care resistance testing in LMICs.

Increasing pre-ART HIV drug-resistance levels, combined with better tolerability, efficacy, and the high-resistance barrier of dolutegravir-based ART, support a recent WHO recommendation for integrase strand transfer inhibitor-based ART as the new preferred first-line ART in LMICs to provide improved viral suppression and limit resistance development. Dolutegravir-based ART as a first-line regimen was introduced in Brazil and Botswana in 2017, and several other LMICs are in the process of doing the same.

## CONCLUSIONS

Although there has been progress toward achieving the third “90,” many challenges remain, particularly for vulnerable and key populations. Even as successes and challenges toward “90-90-90 by 2020” are outlined, new fast-track “95-95-95 by 2030” targets have been established due to concerns that the original targets may not achieve epidemic control. Regardless of a specific target, efforts to scale up evidence-based strategies that are generalizable, cost-effective, community-based, and acceptable to persons living with HIV must be intensified.

## Notes

**Acknowledgments.** We are in debt to Dr Wafaa El-Sadr, Director of the International Center for AIDS Care and Treatment Programs at Columbia

University, Mailman School of Public Health and Professor of Epidemiology and Medicine, Columbia University, NY, NY, USA and Dr Gert Van Zyl, Associate Professor, Division of Medical Virology, Stellenbosch University, Cape Town, South Africa, for their valuable advice.

**Financial support.** J. B. N. receives research grant support from the US National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases, the AIDS Clinical Trial Group/Stellenbosch University Clinical Trial Unit (2UM1A1069521-08); and the Pittsburgh-Stellenbosch University AIDS-Comorbidities Training Research Program (Pitt-SU AICoTRP; NIH/FIC 1D43TW010340-01). N.A.S.A. is supported by funding from the Eunice Kennedy Shriver National Institute of Child Health and Human Development of the NIH through award number R01HD089871.

**Potential conflicts of interest.** J. W. M. is a consultant to Gilead Sciences and owns share options in Co-Crystal Pharmaceuticals, Inc. All other authors report no potential conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

## References

- UNAIDS. 90-90-90: an ambitious treatment target to help end the AIDS epidemic. Available at: [http://www.unaids.org/sites/default/files/media\\_asset/90-90-90\\_en\\_0.pdf](http://www.unaids.org/sites/default/files/media_asset/90-90-90_en_0.pdf) Accessed 8 November 2017.
- UNAIDS. Ending AIDS. Progress toward the 90-90-90 targets, 2017. Available at: [http://www.unaids.org/sites/default/files/media\\_asset/Global\\_AIDS\\_update\\_2017\\_en.pdf](http://www.unaids.org/sites/default/files/media_asset/Global_AIDS_update_2017_en.pdf).
- UNAIDS Aidsinfo. Regional Maps, Treatment Cascade 90-90-90: People living with HIV who have suppressed viral loads. <http://aidsinfo.unaids.org/>. Accessed 19 December 2017.
- Grimrud A, Lesosky M, Kalombo C, Bekker LG, Myer L. Implementation and operational research: community-based adherence clubs for the management of stable antiretroviral therapy patients in Cape Town, South Africa: a cohort study. *J Acquir Immune Defic Syndr* 2016; 71:e16–23.
- Bango F, Ashmore J, Wilkinson L, van Cutsem G, Cleary S. Adherence clubs for long-term provision of antiretroviral therapy: cost-effectiveness and access analysis from Khayelitsha, South Africa. *Trop Med Int Health* 2016; 21:1115–23.
- Ministry of Health, Brazil. LEI No 12.842, DE 10 DE JULHO DE 2013. Available at: [http://legislacao.planalto.gov.br/legisla/legislacao.nsf/Viw\\_Identificacao/lei%2012.842-2013?OpenDocument](http://legislacao.planalto.gov.br/legisla/legislacao.nsf/Viw_Identificacao/lei%2012.842-2013?OpenDocument). Accessed 29 January 2018.
- Ford N, Migone C, Calmy A, et al. Benefits and risks of rapid initiation of antiretroviral therapy. *AIDS* 2018; 32:17–23.
- Bahr N, Boulware DR, Marais S, Scriven J, Wilkinson RJ, Meintjes G. Central nervous system immune reconstitution inflammatory syndrome. *Curr Infect Dis Rep* 2013; 15:583–93.
- Uthman OA, Okwundu C, Gbenga K, et al. Optimal timing of antiretroviral therapy initiation for HIV-infected adults with newly diagnosed pulmonary tuberculosis: a systematic review and meta-analysis. *Ann Intern Med* 2015; 163:32–9.

- Myer L, Essajee S, Broyles LN, et al. Pregnant and breastfeeding women: a priority population for HIV viral load monitoring. *PLoS Med* 2017; 14:e1002375.
- Lesosky M, Glass T, Hsiao N-Y, Abrams EJ, Myer L. Optimal timing of viral load monitoring during pregnancy to predict viraemia at delivery in HIV-infected women initiating ART in South Africa: a simulation study. *J Internat AIDS Soc* 2017; 20(suppl 7):e25000.
- World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and prevention HIV infection—recommendations for a public health approach. 2nd ed. Geneva, Switzerland: WHO; 2016.
- Myer L, Dunning L, Lesosky M, et al. Frequency of viremic episodes in HIV-infected women initiating antiretroviral therapy during pregnancy: a cohort study. *Clin Infect Dis* 2017; 64:422–7.
- Chetty T, Newell ML, Thorne C, Coutsooudis A. Viremia before, during and after pregnancy in HIV-infected women on antiretroviral therapy in rural KwaZulu-Natal, South Africa, 2010–2015. *Trop Med Int Health* 2018 Jan; 23(1):79–91.
- Phillips T, McNairy ML, Zerbe A, Myer L, Abrams EJ. Implementation and operational research: postpartum transfer of care among HIV-infected women initiating antiretroviral therapy during pregnancy. *J Acquir Immune Defic Syndr* 2015; 70:e102–9.
- Myer L, Iyun V, Zerbe A, et al. Differentiated models of care for postpartum women on antiretroviral therapy in Cape Town, South Africa: a cohort study. *J Int AIDS Soc* 2017; 20:21636.
- Koss CA, Natureeba P, Kwarisiima D, et al. Viral suppression and retention in care up to 5 years after initiation of lifelong ART during pregnancy (Option B+) in Rural Uganda. *J Acquir Immune Defic Syndr* 2017; 74:279–84.
- Sam-Agudu NA, Ramadhani HO, Isah C, et al. The impact of structured mentor mother programs on 6-month postpartum retention and viral suppression among HIV-positive women in rural Nigeria: a prospective paired cohort study. *J Acquir Immune Defic Syndr* 2017; 75(suppl 2):173–81.
- Nachege JB, Skinner D, Jennings L, et al. Acceptability and feasibility of mHealth and community-based directly observed antiretroviral therapy to prevent mother-to-child HIV transmission in South African pregnant women under Option B+: an exploratory study. *Patient Prefer Adherence* 2016; 10:683–90.
- Gilbert L, Raj A, Hien D, Stockman J, Terlikbayeva A, Wyatt G. Targeting the SAVA (Substance Abuse, Violence, and AIDS) syndemic among women and girls: a global review of epidemiology and integrated interventions. *J Acquir Immune Defic Syndr* 2015; 69(suppl 2):S118–27.
- Boerma RS, Boender TS, Bussink AP, et al. Suboptimal viral suppression rates among HIV-infected children in low- and middle-income countries: a meta-analysis. *Clin Infect Dis* 2016; 63:1645–54.
- Jiamsakul A, Kariminia A, Althoff KN, et al. HIV viral load suppression in adults and children receiving antiretroviral therapy—results from the IeDEA collaboration. *J Acquir Immune Defic Syndr* 2017; 76:319–29.
- Kim SH, Gerver SM, Fidler S, Ward H. Adherence to antiretroviral therapy in adolescents living with HIV: systematic review and meta-analysis. *AIDS* 2014; 28:1945–56.
- Kwarisiima D, Kanya MR, Owaraganise A, et al. High rates of viral suppression in adults and children with high CD4+ counts using a streamlined ART delivery model in the SEARCH trial in rural Uganda and Kenya. *J Int AIDS Soc* 2017; 20:21673.



25. Ferrand RA, Simms V, Dauya E, et al. The effect of community-based support for caregivers on the risk of virological failure in children and adolescents with HIV in Harare, Zimbabwe (ZENITH): an open-label, randomised controlled trial. *Lancet Child Adolesc Health* **2017**; 1:175–83.
26. Luyirika E, Towle MS, Achan J, et al. Scaling up paediatric HIV care with an integrated, family-centred approach: an observational case study from Uganda. *PLoS One* **2013**; 8:e69548.
27. Dahourou DL, Gautier-Lafaye C, Teasdale CA, et al. Transition from paediatric to adult care of adolescents living with HIV in sub-Saharan Africa: challenges, youth-friendly models, and outcomes. *J Int AIDS Soc* **2017**; 20:21528.
28. Castro R, Ribeiro-Alves M, Corrêa RG, et al. The men who have sex with men HIV care cascade in Rio de Janeiro, Brazil. *PLoS One* **2016**; 11:e0157309.
29. Mehta SH, Lucas GM, Solomon S, et al. HIV care continuum among men who have sex with men and persons who inject drugs in India: barriers to successful engagement. *Clin Infect Dis* **2015**; 61:1732–41.
30. Schwartz SR; University of California, San Francisco, Anova Health Institute, and Wits Reproductive Health and HIV Institute. South African health monitoring study (SAHMS), final report: the integrated biological and behavioural survey among female sex workers, South Africa 2013–2014. San Francisco: UCSF, **2015**.
31. Csete J, Kamarulzaman A, Kazatchkine M, et al. Public health and international drug policy. *Lancet* **2016**; 387:1427–80.
32. Kurth AE, Cleland CM, Des Jarlais DC, et al. HIV prevalence, estimated incidence, and risk behaviors among people who inject drugs in Kenya. *J Acquir Immune Defic Syndr* **2015**; 70:420–7.
33. Gaolathe T, Wirth KE, Holme MP, et al; Botswana Combination Prevention Project Study Team. Botswana's progress toward achieving the 2020 UNAIDS 90-90-90 antiretroviral therapy and virological suppression goals: a population-based survey. *Lancet HIV* **2016**; 3:e221–30.
34. Petersen M, Balzer L, Kwarisiima D, et al. Association of implementation of a universal testing and treatment intervention with HIV diagnosis, receipt of antiretroviral therapy, and viral suppression in East Africa. *JAMA* **2017**; 317:2196–206.
35. ICAP-Columbia University Mailman School of Public Health. The Population-Based HIV Impact Assessment (PHIA) project. Available at: <http://phia.icap.columbia.edu/>. Accessed 22 November 2017.
36. Hayes R, Floyd S, Schaap A, et al. Reaching 90-90-90? Findings after 2 years of HPTN 071 (PopART) intervention in Zambia [abstract 1011]. In: Conference on Retroviruses and Opportunistic Infections, 13–16 February 2017, Seattle, Washington, WA, USA. [http://www.croiconference.org/sites/default/files/posters-2017/1011\\_Hayes.pdf](http://www.croiconference.org/sites/default/files/posters-2017/1011_Hayes.pdf). Accessed 9 February 2018.
37. Iwuji CC, Orne-Gliemann J, Larmarange J, et al; ANRS 12249 TasP trial group. Uptake of home-based HIV testing, linkage to care, and community attitudes about ART in Rural KwaZulu-Natal, South Africa: descriptive results from the first phase of the ANRS 12249 TasP cluster-randomised trial. *PLoS Med* **2016**; 13:e1002107.
38. Haberer JE, Sabin L, Amico KR, et al. Improving antiretroviral therapy adherence in resource-limited settings at scale: a discussion of interventions and recommendations. *J Int AIDS Soc* **2017**; 20:21371.
39. Jobanputra K, Parker LA, Azih C, et al. Factors associated with virological failure and suppression after enhanced adherence counselling, in children, adolescents and adults on antiretroviral therapy for HIV in Swaziland. *PLoS One* **2015**; 10:e0116144.
40. Gupta RK, Gregson J, Parkin N, et al. HIV-1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in low-income and middle-income countries: a systematic review and meta-regression analysis. *Lancet Infect Dis* **2017** Dec 5. pii: S1473-3099(17)30702-8. [Epub ahead of print].